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ABSTRACT: Introduction: A epidemic increase in the incidence 
of papillary thyroid carcinoma (PTC) has been happening within 
the last 25 years. The majority of those tumors are low-risk, and 
some studies reported low progression rates of low-risk PTC. 
It suggests that immediate surgery may not be the best option, 
specially when considering the intrinsic risk to a thyroidectomy 
and inconvenience of lifelong hormone replacement. In this 
systematic review we compare the outcomes of active surveillance 
for the primary management of low-risk PTC. Methods: The 
review was conducted based on three studies selected from 
specific databases. These studies followed up low-risk patients 
nonoperatively and surgery was performed if needed. Results: All 
studies reported low percentages of tumor growth and metastatic 
disease during active surveillance. Furthermore, no significant 
differences between immediate surgery and late rescue surgery 
were reported, and active surveillance appears to be cheaper than 
the tradicional conduct. Conclusions: Active surveillance seems 
to be a good alternative for low-risk PTC management, yet, more 
long-term and bigger research is still needed, specially outside of 
a japanese population.
Keywords: Watchful waiting; Thyroid cancer, papillary; Thyroid 
neoplasms.
RESUMO: Introdução: Um grande aumento na incidência 
de carcinoma papilífero de tireoide (PTC) tem ocorrido nos 
últimos 25 anos. A maior parte desses tumores é de baixo risco, 
e alguns estudos indicaram baixas taxas de progressão de PTC 
de baixo risco. O que sugere que o tratamento cirúrgico imediato 
desses tumores pode não ser a melhor opção, principalmente 
quando se considera os riscos de uma tireoidectomia e a 
inconveniência da consequente reposição hormonal para o resto 
da vida. Nessa revisão sistemática compara-se os resultados 
da conduta expectante para PTCs de baixo risco. Métodos: A 
revisão baseia-se em três estudos selecionados de bases de dados 
específicas. Os estudos acompanharam pacientes de baixo risco 
com base na vigilância ativa dos tumores e, quando necessário, 
estes foram removidos cirurgicamente. Resultados: Todos os 
três estudos apresentam baixas taxas de crescimento tumoral 
e desenvolvimento de metástases durante a observação. Além 
disso, não foram notadas diferenças significantes entre cirurgias 
feitas logo após o diagnóstico e aquelas feitas após a observação, 
também, a observação ativa parece ser um método mais barato 
que o tratamento cirúrgico tradicional. Conclusões: A conduta 
expectante se mostra como uma boa opção para PTCs de baixo 
risco, todavia, faz-se necessário estudos maiores e mais longos, 
especialmente em populações que não sejam japonesas.    
Descritores: Conduta expectante; Câncer papilífero da tireoide; 
Neoplasias da glândula tireoide.
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INTRODUCTION
Thyroid carcinoma incidence worldwide has tripled within the last 25 years1. Great part of 
that is due to papillary thyroid cancer (PTC) detection 
in early stages. Surprisingly, thyroid cancer mortality 
remained stable, which leads us to the hypothesis of 
overdiagnosis2. A substantial increase of preemptive exams 
seems to be the cause of this epidemy1,2.
Traditionally, thyroidectomy is recommended in 
the primary management of PTC, followed by the need 
of lifelong hormone replacement therapy1. Considering 
the intrinsic risk to surgery (e.g., hypoparathyroidism and 
vocal cord paralysis due to recurrent laryngeal nerve injury) 
and inconvenience of lifelong hormone replacement, new 
alternatives to thyroidectomy must not be ignored, specially 
to avoid overtreatment of low-risk PTC.
New studies suggest that surgery may not be the 
unique approach for low-risk papillary thyroid cancer. The 
newest guidelines of the American Thyroid Association 
(ATA) points out that subcentimeter low-risk carcinomas, 
when asymptomatic, should receive an ultrassonography 
follow-up4. However, published data about the nonoperative 
management are still scarce. 
Thus, the goal of this review was to compare studies 
which followed low-risk patients nonoperatively, in order 
to determine if the reported results meet the expected low 
percentage of aggravation that would justify the active 
surveillance management. This article’s parameters for 
classification of low-risk PTC are T1a or T1b tumors (i.e., 
primary tumor size ≤ 2 cm), N0 (i.e., no regional lymph 
nodes metastasis), M0 (i.e., no distant metastasis) based 
on the International Union Against Cancer TNM system3.
METHODS
The searches were carried out in two bibliographic 
databases - PubMed and Scopus. When finalizing searches 
on each database, duplicate references were deleted. 
Additionally, a hand search was conducted to assure of the 
newest articles. The searches covered any article published 
in english up to 2019. The terms “thyroid papillary 
carcinoma”, “low-risk”, and “surveillance” were used.
Using the terms, 225 articles were obtained from 
the electronic search. No papers were obtained from the 
hand search. After a general screening using the exclusion 
criteria, 21 articles lasted. Those papers were full-text 
reviewed and 18 were excluded. The excluded papers 
were: reviews,  studies with no data on active surveillance 
or overlapped data with the included studies. We included 
clinical trials or cohorts which used active surveillance 
follow-up after detection of papillary thyroid cancer 
(PTC) classified as low-risk. Eventually, three studies were 
selected, reported by Ito et al.5, Tuttle et al.6, and Sakai et al.7
RESULTS
Study characteristics 
Ito et al.5 included a single active surveillance group 
of 1215 patients with low-risk T1a PTC, 90% (1111/1235) 
of them were women, the mean age of participants was 
not specified, but  14% (169/1235) were < 40 years, 46% 
(570/1235) were 40-59 years, and 40% (496/1235) were ≥ 
60 years. Tumor size was reported as: 26% (324/1235) ≤ 5 
mm; 56% (686/1235) > 5 mm and ≤ 8 mm; 18% (225/1235) 
> 8 mm and ≤ 10 mm. Exclusion criteria were defined 
based on the definition of low-risk: the presence of regional 
lymph-node metastasis (LNM) or distant metastasis; signs 
or symptoms of invasion to the recurrent laryngeal nerve 
or trachea; FNAB (fine needle aspiration biopsy) findings 
suggesting high-grade malignancy; tumors located adjacent 
to the recurrent laryngeal nerve or trachea5. It is important 
to note that Ito et al.5 study lacks a immediate surgery 
control group.
Tuttle et al.6 observed a single cohort of 291 patients 
under active surveillance with low-risk ≤ 1.5 cm PTC. 
75.3% (219/291) were women, the mean age was 51 years 
(range 20-86), 79.7% (232/291) with tumors ≤ 1 cm and 
20.3% (59/291) with tumors 1.1-1.5 cm. Exclusion criteria 
were also established based on the low-risk definition3,6. 
Sakai et al.7 observed three groups in his study. Two 
of them were active surveillance groups, however the third 
received surgery at diagnosis. The first group had the same 
tumor classification of Ito et al.5 study: 360 patients with 
low-risk T1a PTC, 89% (319/360) were women, mean 
age was 53.9 years (SD 12; range 23-84), and mean tumor 
size was 7.6 mm (SD 1.8; range 2-10). The second group 
had 61 patients with low-risk T1b PTC, 77% (47/61) were 
women, mean age was 54.4 years (SD 10.7; range 32-78), 
and mean tumor size was 11.7mm (SD 1.1; range 11-16). 
The third group was compound of 331 patients with low-
risk T1b PTC that underwent immediate surgery rather 
than active surveillance management, 84% (279/331) were 
women, mean age was 51.9 years (SD 12.6; range 17-82), 
and mean tumor size was 14.5 mm (SD 2.8; range 11-20). 
Exclusion criteria were based on the low-risk definition 
as well3,7. It is important to note that mean tumor size of 
T1b immediate surgery group is significantly bigger when 
compared to T1b active surveillance group. 
All studies followed their patients with clinical 
examination (e.g., palpation) and medical imaging (e.g., 
neck US) every 6 or 12 months in order to check for tumor 
enlargement, development of LNM or distant metastasis. 
Also, the studies defined “tumor enlargement” as a 3 mm 
increase or more when compared to the tumor size at 
diagnosis5,6,7.
405
Rev Med (São Paulo). 2019 Nov-Dec;98(6):403-7.
For Ito et al.5, surgery triggers were tumor enlarged 
to 12mm or development of LNM5. Tuttle et al.6 and 
Sakai et al.7 established different triggers: tumor at risk 
for extrathyroidal extension; primary tumor enlargement; 
development of LNM; development of distant metastasis. 
Sakai et al.7 also defined change in the patient preference 
as a surgery trigger7. 
In Ito et al.5 and Sakai et al.7 studies partial 
thyroidectomy with prophylactic central neck dissection 
was performed as a principal procedure for those with 
solitary lesions and no evidence of nodal involvement. 
Total thyroidectomy associated with more extensive 
nodal dissection was carried out only for those who has 
shown more advanced tumors5,7. In each of these studies, 
participants who underwent surgery either at diagnosis 
or after surveillance were followed by US and chest 
radiography or CT scan annually to monitor for signs 
of recurrence5,7. Tuttle et al.6 did not provide data about 
surgery protocols. The study characteristics are summarized 
in Table 1.
Table 1. Study Characteristics
Ito et al.5 Tuttle et al.6 Sakai et al.7
TNM Classification T1a T1a/T1b T1a T1b
Patients
(women rate)
1235
(90%)
291
(75.3%)
360
(89%)
61
(77%)
Age
14% < 40 years
46% 40-59 years
40% ≥ 60 years
Mean 51 years
(range 20-86)
Mean 53.9 years
(range 23-84)
Mean 54.4 years
(range 32-78)
Tumor Size
26% ≤ 5 mm
56% 5-8 mm
18% 8-10 mm
79.7% ≤ 1 cm
20.3% 1.1-1.5 cm
Mean 7.6 mm
(range 2-10)
Mean 11.7 mm
(range 11-16)
Studies Results
- Active Surveillance Outcomes
Ito et al.5 reported a primary tumor enlargement ≥ 3 
mm in 4.6%, and new nodal metastatic disease in 1.5% of 
T1a patients after a mean follow-up period of 5 years (range 
1.5-18.9). Tuttle et al.6 reported primary tumor enlargement 
≥ 3 mm in 3.8% of patients, and no new nodal metastatic 
disease was related after a mean follow-up period of 2.1 
years (range 0.5-13.8). Sakai et al.7 reported primary tumor 
enlargement ≥ 3 mm in 8% of T1a patients, and 7% of T1b 
patients, new nodal metastatic disease in 1% of T1a and 
3% of T1b patients, after a mean follow-up period of 7.3 
years (range 0.5-25) and 7.9 years (range 1-17) for T1a and 
T1b groups, respectively. 
Ito et al.5 reported a clinical disease progression 
rate of 3.5% (i.e., tumor size reaching at least 12 mm or 
novel appearance of LNM); neither PTC-related deaths, 
nor distant metastasis were seen in this study. Tuttle et al.6 
reported a primary tumor enlargement cumulative incidence 
of 2.5% (2 years) and 12.1% (5 years); no regional or distant 
metastasis were developed, and PTC-related deaths were 
not specifically mentioned. Sakai et al.7 reported a 5-year 
progression rate of 5% and a 10-year progression rate of 
12% for both T1a and T1b groups (“progression” was 
defined as a ≥ 3 mm tumor enlargement or development 
of metastasis); although, neither PTC-related deaths, nor 
distant metastasis cases were specifically mentioned in 
active surveillance outcomes of this study, which lead us 
to believe that they did not occur.  
Ito et al.5 multivariate analysis among T1a patients 
adjusted for relevant factors (e.g. family history and 
age) reported young age (< 40 years) as an independent 
predictive of tumor enlargement ≥ 3 mm (OR 2.5; 
P=0,0033), incidence of nodal metastasis (OR 6.757; 
P<0,0001) and progression to clinical disease (i.e., tumor 
enlarged to 12 mm or incident nodal metastasis) (OR 4.348; 
P<0,0001); furthermore, this study reported that primary 
tumor size 9mm or larger was also an independent predictor 
of progression to clinical disease (OR 4.717; P=0.0005)5. 
Tuttle et al.6 multivariate analysis also concluded that 
young age at diagnosis is an independent predictive of 
tumor enlargement ≥ 3 mm (hazard ratio per year, 0.92; 
95% CI, 0.87-0.98; P=0.006). Sakai et al.7 univariate 
analysis among only T1b patients concluded that non-
calcification pattern and rich vascularity were risk factors 
for tumor enlargement, while lower age was associated 
with LNM development [mean age of no-development 
and development group were 55 (SD 10.3; P=0.02) and 
37.5 (SD 7.8; P=0.02), respectively]. Active surveillance 
outcomes are summarized in Table 2. 
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Table 2. Active surveillance outcomes.
Ito et al.5 Tuttle et al.6 Sakai et al.7
TNM Classification T1a T1a/T1b T1a T1b
Mean Follow-up Period 
(range)
5 years
(1.5-18.9)
2.1 years
(0.5-13.8)
7.3 years
(0.5-25)
7.9 years
(1-17)
Tumor Enlargement 4.6% 3.8% 8% 7%
LNM Development 1.5% none 1% 3%
Distant Metastasis none none - -
PTC-related Deaths none - - -
- Surgery Outcomes
In Ito et al.5 study 15% (191/1235) of T1a patients 
underwent late rescue surgery (i.e., surgery triggered after 
active surveillance). After a mean postoperative follow-up 
of 6.2 years, only one case of recurrence was related, which 
occurred in the remnant thyroid 130 months after surgery.
Among Tuttle et al.6 patients, 3.5% (10/291) 
underwent surgery. Only half of them had previously shown 
tumor enlargement. After a mean postoperative follow-up 
of 0.6 years (range 0.25-2.6) no recurrent disease was seen. 
Sakai et al.7 did not report T1a surgery outcomes, 
however, T1b surgery outcomes were described for both 
immediate surgery and active surveillance groups. Among 
the total of 331 T1b immediate surgery patients, 8 showed 
recurrence: at the remnant thyroid (2 cases), at lymph 
nodes (5 cases), and at distant sites (1 case). Recurrence 
only occurred in patients with tumors larger than 15 
mm7. In the T1b active surveillance group, 18% (11/61) 
underwent surgery. None of them showed recurrence 
during the follow-up period. It is important to mention that 
mean postoperative follow-up period of both groups were 
not specified, also no significant differences in surgical 
procedures, complications, or overall rate of recurrence 
were noted between T1b immediate surgery group and T1b 
active surveillance group7. Late rescue surgery outcomes 
are summarized in Table 3.
Table 3. Late rescue surgery outcomes
Ito et al.5 Tuttle et al.6 Sakai et al.7
TNM Classification T1a T1a/T1b T1a T1b
Thyroidectomy Rate 15% (191/1235) 3.5% (10/291) - 18% (11/61)
Mean Postoperative Follow-
up Period 6.2 years 0.6 years - -
Recurrent Disease 1 case none - none
DISCUSSION
Low-risk PTC progression (i.e., LNM development 
or tumor enlargement) rates were similarly low during 
active surveillance in all of the three studies analyzed. 
Neither PTC-related deaths nor distant metastasis were 
related (in some cases the absence of these events was not 
specifically mentioned, which appears to imply that they 
did not occur). Furthermore, no significant differences 
were reported between immediate surgery and “late 
rescue surgery” of T1a and T1b tumors7. Yet, the studies 
presented disparate thyroidectomy rates, which seems to 
be a consequence of differents surgery triggers. 
Although the published literature about active 
surveillance management is concentrated almost 
exclusively in Japanese centers (such as Ito et al.5 and 
Sakai et al.7 studies), the similarly excellent results reported 
by Tuttle et al.6 suggests that this nonsurgical approach is 
able to be implemented outside of a Japanese population. 
Moreover, the published literature mainly comprehended 
subcentimeter tumors (i.e., T1a), still the equally great 
results reported by Sakai et al.7 suggest that low-risk T1b 
tumors are also eligible candidates for active surveillance.
At Kuma Hospital, where Ito et al.5 study was 
conducted, a comparison of the costs of active surveillance 
and immediate surgery in the management of low-risk T1a 
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PTC shown that in 10 years the total cost of immediate 
surgery was approximately 4.1 times higher than the non-
operative management8. 
In conclusion, considering the inconvenience of 
thyroid ablation and the favorable results reported by 
the presented studies, active surveillance seems to be a 
beneficial and cost-effective choice for low-risk Papillary 
Thyroid Carcinoma management, even for some T1b 
tumors. Yet, studies with longer follow-up period and 
higher number of participants are needed, specially those 
involving non-japanese patients and T1b tumors.    
Contribuição dos autores: Furukawa C - levantamento bibliográfico; escrita da introdução, resultados e conclusões; revisão final. Hage 
Fabri LA - levantamento bibliográfico; escrita dos métodos; revisão final. Hojaij F – Orientador, revisão final.
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